Literature DB >> 4207623

A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.

E H Vallota, O Götze, H L Spiegelberg, J Forristal, C D West, H J Müller-Eberhard.   

Abstract

Nephritic factor (C3NeF) has been isolated from plasma of patients with hypocomplementemic chronic glomerulonephritis (HCG) by ion exchange and molecular sieve chromatography. This material was further treated with solidified anti-Ig antiserum. The purified material failed to react with antiserum to human IgG, IgG3, Fab, Fc, and kappa and lambda chains, but retained full C3NeF activity. The nonidentity of C3NeF with IgG was further demonstrated by Ouchterlony analysis using anti-IgG and anti-C3NeF. Isolated C3NeF was found to be a protein with a sedimentation coefficient of 7S and a mol wt of 150,000 daltons, which on microzone electrophoresis and gel electrophoresis at pH 8.6 behaved as a gamma-globulin. C3NeF is not a C1q precipitin and does not activate the classical complement pathway. Unlike cobra venom factor, it failed to enter into a complex with C3 proactivator (C3PA) when incubated with normal human serum (NHS) and then subjected to sucrose density gradient ultracentrifugation. The action of isolated C3NeF on C3 requires C3PA, C3PA convertase (C3PAse), and properdin (P). Similarly, C3PA conversion by C3NeF requires P, C3PAse, and C3. Total hemolytic activity was lost by incubation of 64 microg of C3NeF/1 ml NHS at 37 degrees C for 30 min. Both C3a and C5a anaphylatoxin could be generated by C3NeF in serum previously depleted of anaphylatoxin inactivator. Anti-C3NeF was found to detect an antigen in all NHS tested. Treatment of NHS with solidified anti-C3NeF caused impairment of the alternate complement pathway. It failed to sustain lysis of glutathione-treated human erythrocytes initiated by inulin. It is conceivable that the normal serum constituent which is removed by anti-C3NeF constitutes the inactive precursor of C3NeF, and a heretofore unrecognized component of the alternate pathway.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4207623      PMCID: PMC2139648          DOI: 10.1084/jem.139.5.1249

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  Dissociation of antibody from erythrocyte surfaces by chaotropic ions.

Authors:  T S Edgington
Journal:  J Immunol       Date:  1971-03       Impact factor: 5.422

2.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

3.  Biologically active water-insoluble protein polymers. I. Their use for isolation of antigens and antibodies.

Authors:  S Avrameas; T Ternynck
Journal:  J Biol Chem       Date:  1967-04-10       Impact factor: 5.157

4.  The C3 nephritic factor and membranoproliferative nephritis: correlation of serum levels of the nephritic factor with C3 levels, with therapy, and with progression of the disease.

Authors:  E H Vallota; J Forristal; N C Davis; C D West
Journal:  J Pediatr       Date:  1972-06       Impact factor: 4.406

5.  C3 inactivating factor in the serum of a patient with chronic hypocomplementaemic proliferative glomerulo-nephritis.

Authors:  R A Thompson
Journal:  Immunology       Date:  1972-01       Impact factor: 7.397

6.  Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation.

Authors:  L G Hunsicker; S Ruddy; C B Carpenter; P H Schur; J P Merrill; H J Müller-Eberhard; K F Austen
Journal:  N Engl J Med       Date:  1972-10-26       Impact factor: 91.245

7.  Continuing C3 breakdown after bilateral nephrectomy in patients with membrano-proliferative glomerulonephritis.

Authors:  E H Vallota; J Forristal; R E Spitzer; N C Davis; C D West
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

8.  Evidence for in vivo breakdown of beta-10-globulin in hypocomplementemic glomerulonephritis.

Authors:  C D West; S Winter; J Forristal; J M McConville; N C Davis
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

9.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

10.  Characteristics of a non-complement-dependent C3-reactive complex formed form factors in nephritic and normal serum.

Authors:  E H Vallota; J Forristal; R E Spitzer; N C Davis; C D West
Journal:  J Exp Med       Date:  1970-06-01       Impact factor: 14.307

View more
  25 in total

1.  Membranoproliferative glomerulonephritis with partial lipodystrophy: discordant occurrence in identical twins.

Authors:  W Reichel; J Köbberling; H Fischbach; F Scheler
Journal:  Klin Wochenschr       Date:  1976-01-15

2.  Identification of nephritic factor as an immunoglobulin.

Authors:  D G Williams; A Bartlett; P Duffus
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

Review 3.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

4.  Editorial: Complement activation and disease.

Authors: 
Journal:  Br Med J       Date:  1976-02-21

5.  The immunogloblin nature of nephritic factor (NeF).

Authors:  D M Scott; N Amos; J G Sissons; P J Lachmann; D K Peters
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

6.  Heterogeneity of nephritic factor and its identification as an immunoglobulin.

Authors:  A E Davis; J B Ziegler; E W Gelfand; F S Rosen; C A Alper
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

Review 7.  Novel biomarkers in glomerular disease.

Authors:  Yasar Caliskan; Krzysztof Kiryluk
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

Review 8.  Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.

Authors:  Y Levy; J George; E Yona; Y Shoenfeld
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

9.  Activation of the alternative complement pathway in systemic lupus erythematosus.

Authors:  M R Wilson; C M Arroyave; R M Nakamura; J H Vaughan; E M Tan
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

10.  Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.

Authors:  C Adam; D G Williams; D K Peters
Journal:  Clin Exp Immunol       Date:  1975-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.